Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of Fleximer conjugates for oncology, today announced its participation in the upcoming Annual Meeting of the American Association of Cancer Research (AACR).

Timothy B. Lowinger, Ph.D., Chief Scientific Officer, will present a poster in the New Antibodies and Antibody Drug Conjugates session at the 2014 Annual Meeting of the American Association of Cancer Research (AACR) taking place April 5-9, 2014, at the San Diego Convention Center in San Diego, California. Abstract #2645, “Advantages of polyacetal polymer-based ADCs: Application to low expression targets,” will be presented on Monday, April 7, 2014, from 1:00 p.m. to 5:00 p.m. in Hall A-E, Poster Section 31.

About Mersana Therapeutics, Inc.

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Mersana is developing, with select pharmaceutical partners, a portfolio of next-generation Fleximer-ADCs with superior properties not found with direct conjugation ADC technologies. The company is also advancing its own pipeline of Fleximer-ADCs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications.

Media Contact

 MacDougall Biomedical Communications
 Kari Watson
 kwatson@macbiocom.com
 781-235-3060